Abreu MT - Search Results

1

Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease.

Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, McGovern DP, Abreu MT, Melmed G, Shaye O, Enayati P, Chen G, Choi J, Taylor K, Landers CJ, Rotter JI, Targan SR. Ippoliti A, et al. Among authors: abreu mt. Inflamm Bowel Dis. 2010 Aug;16(8):1279-85. doi: 10.1002/ibd.21196. Inflamm Bowel Dis. 2010. PMID: 20027650 Free PMC article.

2

Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease.

Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Hassard PV, et al. Among authors: abreu mt. Inflamm Bowel Dis. 2000 Feb;6(1):16-20. doi: 10.1097/00054725-200002000-00003. Inflamm Bowel Dis. 2000. PMID: 10701145

3

Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.

Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Papadakis KA, et al. Among authors: abreu mt. Am J Gastroenterol. 2001 Jul;96(7):2137-42. doi: 10.1111/j.1572-0241.2001.03949.x. Am J Gastroenterol. 2001. PMID: 11467645

4

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.

Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Among authors: abreu mt. Inflamm Bowel Dis. 2001 Aug;7(3):181-9. doi: 10.1097/00054725-200108000-00001. Inflamm Bowel Dis. 2001. PMID: 11515842 Clinical Trial.

5

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Among authors: abreu mt. Gastroenterology. 2002 Apr;122(4):904-15. doi: 10.1053/gast.2002.32420. Gastroenterology. 2002. PMID: 11910342 Clinical Trial.

6

Controversies in IBD. Serologic tests are helpful in managing inflammatory bowel disease.

Abreu MT. Abreu MT. Inflamm Bowel Dis. 2002 May;8(3):224-6; discussion 223, 230-1. doi: 10.1097/00054725-200205000-00012. Inflamm Bowel Dis. 2002. PMID: 11979146 No abstract available.

7

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease.

Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Abreu MT, et al. Gastroenterology. 2002 Sep;123(3):679-88. doi: 10.1053/gast.2002.35393. Gastroenterology. 2002. PMID: 12198692

8

Defining subtypes of Crohn's disease patients: the ground work for translational research in inflammatory bowel disease.

Abreu MT, Yang H. Abreu MT, et al. J Clin Gastroenterol. 2003 Jan;36(1):3-4. doi: 10.1097/00004836-200301000-00002. J Clin Gastroenterol. 2003. PMID: 12488696 No abstract available.

9

Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut.

Melmed G, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, Zhou Y, Hu B, Arditi M, Abreu MT. Melmed G, et al. Among authors: abreu mt. J Immunol. 2003 Feb 1;170(3):1406-15. doi: 10.4049/jimmunol.170.3.1406. J Immunol. 2003. PMID: 12538701

10

Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.

Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Among authors: abreu mt. Am J Gastroenterol. 2003 May;98(5):1058-63. doi: 10.1111/j.1572-0241.2003.07413.x. Am J Gastroenterol. 2003. PMID: 12809828

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

291 results

Search Page

Filters